

Lemtrada

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:			
Patient's ID:	Patient's Date of Birth:			
Physician's Name:				
Specialty:	NPI#:			
Physician Office Telephone:	Physician Office Fax:			
Referring Provider Info: ☐ Same as Requesting Provider				
Name:	NPI#:			
Fax:	Phone:			
Rendering Provider Info: □ Same as Referring Provider □ Same as Requesting Provider Name: NPI#:				
Fax:	Phone:			
Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.				
Required Demographic Information:				
Patient Weight:	kg			
Patient Height:	cm			
What is the ICD-10 code?				

Site	e of Service Questions:	
	Where will this drug be administered? ☐ Ambulatory surgical, skip to Clinical Criteria Questions ☐ Home infusion, skip to Clinical Criteria Questions ☐ Off-campus Outpatient Hospital, Continue to B ☐ On-campus Outpatient Hospital, Continue to B ☐ Physician office, skip to Clinical Criteria Questions ☐ Pharmacy, skip to Clinical Criteria Questions	
B.	Is the patient less than 14 years of age? ☐ Yes, skip to Clinical Criteria Questions ☐ No, Continue to C	
C.	Is this request to continue previously established treatment with the requested medication? ACTION REQUIRED If No, please attach supporting clinical documentation. Yes - This is a continuation of an existing treatment., Continue to D No - This is a new therapy request (patient has not received requested medication in the last 6 months)., skip to Clinical Criteria Questions	
D.	Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, or other pre-medications) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? <i>ACTION REQUIRED: If Yes, please attach supporting clinical documentation.</i> □ Yes, <i>skip to Clinical Criteria Questions</i> □ No, <i>Continue to E</i>	
E.	Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? **ACTION REQUIRED: If Yes, please attach supporting clinical documentation.** Description: No, Continue to F	
F.	Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? <i>ACTION REQUIRED: If Yes, please attach supporting clinical documentation.</i> \square Yes, <i>skip to Clinical Criteria Questions</i> \square No, <i>Continue to G</i>	
G.	Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? <i>ACTION REQUIRED: If Yes, please attach supporting clinical documentation.</i> □ Yes, <i>skip to Clinical Criteria Questions</i> □ No, <i>Continue to H</i>	
Н.	Are <i>all</i> alternative infusion sites (pharmacy, physician office, ambulatory care, etc.) greater than 30 miles from the patient's home? <i>ACTION REQUIRED: If Yes, please attach supporting documentation</i> . Yes, continue to Clinical Criteria Questions No, continue to Clinical Criteria Questions	

Prescriber or Authorized Signature	Date (mm/dd/yy)
I attest that this information is accurate and true, and the information is available for review if requested by CVS (** 0
8. Will the patient start treatment at least 12 months after the l ☐ Yes, No Further Questions ☐ No, No Further Questions	ast dose of the prior treatment course?
7. Has the patient had an inadequate response to two or more of Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	drugs indicated for multiple sclerosis?
6. How many courses of the requested medication has the pating No previous courses, <i>Continue to 7</i> ☐ One course or more (5 doses or more), <i>Continue to 8</i>	ent previously received?
5. Has the prescriber evaluated the risks and benefits of treatm ☐ Yes, <i>Continue to 6</i> ☐ No, <i>Continue to 6</i>	ent and attests the benefits outweigh the risks?
 4. What is the patient's age? ☐ Less than 18 years of age, Continue to 5 ☐ Greater than or equal to 18 years of age, Continue to 6 	
3. Will the requested medication be prescribed by or in consul ☐ Yes, Continue to 4 ☐ No, Continue to 4	tation with a neurologist?
2. Is the patient taking the requested medication with any othe (Note: Ampyra and Nuedexta are not disease modifying.) ☐ Yes, Continue to 3 ☐ No, Continue to 3	r disease modifying multiple sclerosis (MS) agent?
☐ Other, please specify, Cont	inue to 2
☐ Relapsing form of multiple sclerosis (including relapsing-rethose who continue to experience relapse), <i>Continue to 2</i> ☐ Primary progressive multiple sclerosis, <i>Continue to 2</i>	emitting and secondary progressive disease for
Clinical Criteria Questions: 1. What is the patient's diagnosis?	

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please